NCT06982079 Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
| NCT ID | NCT06982079 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Ain Shams University |
| Condition | Chronic Kidney Disease Stage 5 |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 60 participants in total. It began in 2025-05-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate whether dapagliflozin can reduce the risk of worsening kidney function or death from cardiovascular or renal causes in adults with advanced chronic kidney disease (CKD), with or without type 2 diabetes. The main questions it aims to answer are: 1. Does dapagliflozin reduce the rate of decline in kidney function or progression to end-stage kidney disease in adults with advanced CKD? 2. Does dapagliflozin reduce the risk of death from cardiovascular or renal causes in patients with advanced CKD? Researchers will compare dapagliflozin to a placebo to see if dapagliflozin improves kidney and cardiovascular outcomes in this high-risk population.
Eligibility Criteria
Inclusion Criteria: * Adult patients aged eighteen or older. * Patients with advanced chronic kidney disease (i.e., eGFR \< 20 mL/min/1.73m2)not on dialysis Exclusion Criteria: * Autosomal dominant polycystic kidney disease (ADPKD). * Type 1 diabetes mellitus * Patients on SGLT2 inhibitors. * History of ketoacidosis in the last 3 months. * Known hypersensitivity to SGLT2 inhibitors. * Known hepatic impairment. * Pregnant or breastfeeding females.
Frequently Asked Questions
Who can join the NCT06982079 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Kidney Disease Stage 5. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06982079 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 60 participants.
Is NCT06982079 currently recruiting?
Yes, NCT06982079 is actively recruiting participants. Visit ClinicalTrials.gov or contact Ain Shams University to inquire about joining.
Where is the NCT06982079 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06982079 clinical trial?
NCT06982079 is sponsored by Ain Shams University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.